Pierluigi Porcu
Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Credentials: · · · ·
History
PresentHematology and Cellular Therapy Division · University of Kentucky College of Medicine
- 1987–1990
Internal Medicine
Research
Blood · 2010 · 686 citations
The Lancet Oncology · 2018 · 552 citations
Journal of Clinical Oncology · 2015 · 342 citations
35 papers · 7 as a fellow
- JB
29 papers
- MC
27 papers
27 papers
26 papers
- SH
25 papers
- YK
20 papers
18 papers · 5 as a fellow
Grants
- 2023–2029
EBNA1 Inhibitor for Treatment of EBV-Positive DLBCL
National Cancer Institute · R01
PI · $1.8M · Wistar Institute
- 2012–2014
Novel Biomarkers in Cutaneous T Cell Lymphoma
National Cancer Institute · R21
PI · $354.9K · Ohio State University
- 2003–2008
Combined Cytokine-Monoclonal Antibody Therapy in Lymphoma
National Cancer Institute · K23
Contact PI · $677.6K · Ohio State University
- 2003–2004
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $68.9K · Ohio State University
Clinical trials
- 2026–2028
Principal investigator · Recruiting · Phase 1
Pierluigi Porcu
- 2010–2012
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Principal investigator · Completed · Phase 1
Pierluigi Porcu
- 2004–2016
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Principal investigator · Completed · Phase 1
Ohio State University Comprehensive Cancer Center
- 2000
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)